The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
- AstraZeneca’s Novel RA Drug Fostamatinib Fails to Demonstrate Non-Inferiority to Humira in PIIb Study
December 17, 2012
- Eli Lilly to Conduct Additional Trial of Novel AD Treatment Solanezumab
December 17, 2012
- Eli Lilly to Discontinue One of Three PIII Rheumatoid Arthritis Registration Studies of Tabalumab
December 17, 2012
- Janssen Research & Development Submits NDA for Canagliflozin/Metformin Fixed-Dose Combination in the US
December 17, 2012
- Eisai Concludes Strategic Manufacturing Alliance with Biogen Idec for Contract Manufacturing at Eisai Inc.’s US Plant
December 17, 2012
- Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
- Calls by MRs from Pfizer Japan Left Best Impression at Insurance Pharmacies in October: Nextit Research
December 14, 2012
- ADCETRIS Shows Tolerability in Untreated HL Patients: Takeda
December 14, 2012
- Lyrica, Other Key Products Upbeat in FY2012 Despite NHI Price Revision: Pfizer Japan Pres. Umeda
December 13, 2012
- Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
- Astellas Initiates PIII Study of Oral Renal Anemia Treatment in US, Europe
December 13, 2012
- Importance of Alliances Increasing in Competitive Diabetes Drug Market
December 13, 2012
- About 50% of FLT3-ITD Positive Patients Achieve CRc in PII Study for Quizartinib: Astellas
December 13, 2012
- Kaken Initiates Voluntary Partial Recall of Empynase-P Tablets 18000
December 13, 2012
- UMN Pharma Listed on TSE Mothers, Sets Midterm Plan Target to Be in Black
December 13, 2012
- Domestic Drug Makers Need to Break from Closed Innovation and Promote Open Innovation: Prof. Teranishi of Kyoto Univ. MIC
December 13, 2012
- [Data] Sales of Takeda’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Daiichi Sankyo’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Otsuka HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…